EMD secures MDMA supply for trial
Our psychedelic treatment and care delivery Investment, Emryia (ASX: EMD) has successfully secured a locally-available supply of MDMA through a collaboration with Mind Medicine Australia Australian National University today.
This marks another step forward for EMD, as it prepares to dose its first patient in its Phase 2b MDMA Assisted Therapy trial:
🔄 Begin treatment on first patient (MDMA)
Today’s news was also the final piece of the puzzle for EMD with this trial, after its acquisition of the Pax Centre was completed and ethics approvals were received.
To catch up on EMD read our first two notes on our new Investment:
EMD’s progress comes hot on the heels of a major result for psychedelic therapy last week.
MAPS, a US-based not-for-profit organisation published Phase 3 trial results on MDMA Assisted Therapy (MDMA-AT) for those suffering from Post Traumatic Stress Disorder (PTSD).
Those results outlined how more than two thirds of those receiving the MDMA treatment and the associated therapy no longer had PTSD, and almost half of patients had successfully put their PTSD into remission.
Below is our coverage of those results:
EMD’s peer announce breakthrough results for MDMA therapy
What’s next for EMD?
We think EMD treating its first patient in the MDMA Phase 2b trial could be a catalyst for the company.
Given the recent changes to Australia’s regulatory regime around psychedelic therapies, there’s a chance it could also pick up some additional media coverage.
For a full rundown of what we expect EMD to deliver, read our EMD Investment Memo.
